Merck appeals rofecoxib verdictBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39157.476910.DB (Published 22 March 2007) Cite this as: BMJ 2007;334:607
- Janice Hopkins Tanne
- New York
Merck will appeal against the decision that a New Jersey state court jury made on 12 March to award compensatory and punitive damages of $47.5m (£24.4m; €35.7m) to an Idaho man, Frederick Humeston, and his wife Mary, for a heart attack he had in 2001, when he was 56.
The damages, awarded after the retrial of an earlier case that Mr Humeston lost, were $18m to Mr Humeston, $2m to his wife, and $27.5 in punitive damages. The jury decided that Merck was negligent in not warning Mr Humeston of the risk of taking rofecoxib (Vioxx).
Merck voluntarily withdrew rofecoxib, a cyclo-oxygenase-2 inhibitor, from the market on 30 September 2004 because it increased the risk of heart attacks and strokes (BMJ 2005;329:816).
Merck faces more than 27 000 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial